Charles A Gersbach

Charles Gersbach

Rooney Family Associate Professor of Biomedical Engineering

Appointments and Affiliations

  • Rooney Family Associate Professor of Biomedical Engineering
  • Associate Professor of Biomedical Engineering
  • Associate Professor of Orthopaedic Surgery
  • Affiliate of the Duke Initiative for Science & Society
  • Member of the Duke Cancer Institute

Contact Information

Education

  • Ph.D. Georgia Institute of Technology, 2006
  • B.S. Georgia Institute of Technology, 2001

Research Interests

Dr. Gersbach's research interests are in gene therapy, biomolecular and cellular engineering, regenerative medicine, and synthetic biology.

Specialties

Drug Delivery
Genomics
Tissue Repair, Tissue Engineering
Polymer and Protein Engineering
Biological Materials

Courses Taught

  • BME 260L: Modeling Cellular and Molecular Systems
  • BME 394: Projects in Biomedical Engineering (GE)
  • BME 493: Projects in Biomedical Engineering (GE)
  • BME 494: Projects in Biomedical Engineering (GE)
  • BME 562: Biology by Design (GE, MC)
  • BME 712S: Biological Engineering Seminar Series (CBIMMS and CBTE)
  • BME 791: Graduate Independent Study
  • EGR 391: Projects in Engineering
  • EGR 393: Research Projects in Engineering
  • GENOME 293: Research Independent Study Genome Sciences
  • ME 718S: Biological Engineering Seminar Series (CBIMMS and CBTE)

In the News

Representative Publications

  • Black, JB; Adler, AF; Wang, H-G; D'Ippolito, AM; Hutchinson, HA; Reddy, TE; Pitt, GS; Leong, KW; Gersbach, CA, Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells., Cell Stem Cell, vol 19 no. 3 (2016), pp. 406-414 [10.1016/j.stem.2016.07.001] [abs].
  • Maeder, ML; Gersbach, CA, Genome-editing Technologies for Gene and Cell Therapy., Molecular Therapy, vol 24 no. 3 (2016), pp. 430-446 [10.1038/mt.2016.10] [abs].
  • Thakore, PI; Black, JB; Hilton, IB; Gersbach, CA, Editing the epigenome: technologies for programmable transcription and epigenetic modulation, Nature Methods, vol 13 no. 2 (2016), pp. 127-137 [10.1038/nmeth.3733] [abs].
  • Nelson, CE; Hakim, CH; Ousterout, DG; Thakore, PI; Moreb, EA; Castellanos Rivera, RM; Madhavan, S; Pan, X; Ran, FA; Yan, WX; Asokan, A; Zhang, F; Duan, D; Gersbach, CA, In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy., Science, vol 351 no. 6271 (2016), pp. 403-407 [10.1126/science.aad5143] [abs].
  • Thakore, PI; D'Ippolito, AM; Song, L; Safi, A; Shivakumar, NK; Kabadi, AM; Reddy, TE; Crawford, GE; Gersbach, CA, Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements., Nature Methods, vol 12 no. 12 (2015), pp. 1143-1149 [10.1038/nmeth.3630] [abs].
  • Hilton, IB; D'Ippolito, AM; Vockley, CM; Thakore, PI; Crawford, GE; Reddy, TE; Gersbach, CA, Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers., Nature Biotechnology, vol 33 no. 5 (2015), pp. 510-517 [10.1038/nbt.3199] [abs].
  • Polstein, LR; Gersbach, CA, A light-inducible CRISPR-Cas9 system for control of endogenous gene activation., Nature Chemical Biology, vol 11 no. 3 (2015), pp. 198-200 [10.1038/nchembio.1753] [abs].
  • Ousterout, DG; Kabadi, AM; Thakore, PI; Majoros, WH; Reddy, TE; Gersbach, CA, Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy., Nature Communications, vol 6 (2015) [10.1038/ncomms7244] [abs].
  • Perez-Pinera, P; Kocak, DD; Vockley, CM; Adler, AF; Kabadi, AM; Polstein, LR; Thakore, PI; Glass, KA; Ousterout, DG; Leong, KW; Guilak, F; Crawford, GE; Reddy, TE; Gersbach, CA, RNA-guided gene activation by CRISPR-Cas9-based transcription factors., Nature Methods, vol 10 no. 10 (2013), pp. 973-976 [10.1038/nmeth.2600] [abs].